Study On Correlation Of KIR Gene Polymorphism With The Response To Interferon Therapy And Interferon Antibody In Patients With Chronic Hepatitis B Virus Infection

Objective:By the comprehensive analysis of chronic hepatitis B patients with interferon therapy, whose population KIR gene polymorphism and interferon antibody, to discuss the relation of KIR gene polymorphism with the therapeutic effect of interferon and interferon antibody.Methods:Sixty patients with chronic HBV infection treated with interferon were selected, to detect their interferon antibodies, KIR genes, HBV-DNA loads and related biochemical and immunological testing. According to the response to interferon therapy, the patients were divided into response group and non-response group, KIR genotypes of the two groups were compared statistically. And based on the occurrence of interferon antibody, the subjects were divided into antibody group and non-antibody group, to analyze the differences of the efficacy of interferon and KIR genotypes in the two groups.Results:1. Twenty four KIR gene alleles were detected among all patients of two groups, which were subordinated to seventeen KIR genes. The frequencies of 2DL4,3DL2,3DL3,pseudo gene 3DP1 in two groups, which were the framework genes, were 100%, The allele frequencies of KIR2DL2* 001-005,2DS2* 001-005,3DP1* 001/002/004,2DL5 in the response group were significantly higher than these in the non-response group, while KIR2DS4* 003-007 was significantly lower, the differences were significant (P<0.05). The distribution of other alleles were not significant difference (P> 0.05).2. After treatment of interferon,8 (13.33%) patients were serum anti-IFN antibodies positive, including 6 responders (20%) and 2 no responders (6.67%), the difference was not statistically significant(P= 0.254).3. There were statistically significant between 2DL5B*002/004/007,3DL 1*001-009/015-020,3DPl*003 and the produce of antt-IFN antibodies, the distribution of other alleles was no significant difference.Conclusion:1. KIR2DL2* 001-005,2DS2* 001-005,3 DPI* 001/002/004,2DL5 with chronic HBV may be associated with response to interferon treatment, KIR2DS4* 003-007 may be associated with no response to interferon treatment.2. The rate of anti-interferon antibodies was low, and it has less impact on the efficacy of interferon.3.2DL5B*002/004/007. 3DL1*001-009/015-020 and 3DP1*003 of KIR genotypes may be associated with anti-INF.